Analysts Set Expectations for Exact Sciences FY2025 Earnings

Exact Sciences Corporation (NASDAQ:EXAS) – Equities researchers at William Blair upped their FY2025 earnings estimates for Exact Sciences in a report released on Tuesday, November 4th. William Blair analyst A. Brackmann now expects that the medical research company will earn $0.47 per share for the year, up from their previous forecast of $0.36. The consensus estimate for Exact Sciences’ current full-year earnings is ($0.58) per share. William Blair also issued estimates for Exact Sciences’ Q1 2026 earnings at $0.16 EPS, Q3 2026 earnings at $0.35 EPS and FY2026 earnings at $1.16 EPS.

Several other research analysts have also recently issued reports on EXAS. Wall Street Zen upgraded shares of Exact Sciences from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Guggenheim boosted their price objective on shares of Exact Sciences from $70.00 to $75.00 and gave the company a “buy” rating in a research report on Tuesday. Wells Fargo & Company set a $68.00 target price on shares of Exact Sciences in a report on Wednesday, October 1st. Evercore ISI raised their target price on Exact Sciences from $64.00 to $68.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 7th. Finally, BTIG Research upped their price target on Exact Sciences from $75.00 to $85.00 and gave the company a “buy” rating in a research report on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $72.90.

Exact Sciences Stock Performance

Shares of EXAS stock opened at $69.59 on Wednesday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.56 and a current ratio of 2.89. Exact Sciences has a fifty-two week low of $38.81 and a fifty-two week high of $72.83. The stock has a 50 day moving average price of $56.85 and a two-hundred day moving average price of $53.02. The company has a market capitalization of $13.17 billion, a P/E ratio of -12.82, a PEG ratio of 5.56 and a beta of 1.24.

Exact Sciences (NASDAQ:EXAS) last released its earnings results on Monday, November 3rd. The medical research company reported $0.24 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.11. Exact Sciences had a negative return on equity of 1.75% and a negative net margin of 34.19%.The company had revenue of $850.74 million during the quarter, compared to analyst estimates of $810.42 million. During the same quarter in the previous year, the company posted ($0.21) EPS. Exact Sciences’s revenue for the quarter was up 20.0% on a year-over-year basis. Exact Sciences has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Westside Investment Management Inc. grew its holdings in shares of Exact Sciences by 100.0% during the third quarter. Westside Investment Management Inc. now owns 542 shares of the medical research company’s stock valued at $31,000 after buying an additional 271 shares during the last quarter. True Wealth Design LLC raised its position in Exact Sciences by 951.8% in the 2nd quarter. True Wealth Design LLC now owns 589 shares of the medical research company’s stock worth $31,000 after buying an additional 533 shares during the last quarter. Country Trust Bank bought a new position in Exact Sciences during the 2nd quarter valued at about $32,000. Larson Financial Group LLC boosted its holdings in shares of Exact Sciences by 2,804.8% during the 1st quarter. Larson Financial Group LLC now owns 610 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 589 shares during the last quarter. Finally, Bessemer Group Inc. raised its holdings in shares of Exact Sciences by 1,980.6% during the second quarter. Bessemer Group Inc. now owns 645 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 614 shares during the last quarter. Institutional investors own 88.82% of the company’s stock.

Insider Activity

In related news, Director James Edward Doyle sold 2,000 shares of the company’s stock in a transaction dated Thursday, October 9th. The shares were sold at an average price of $60.00, for a total value of $120,000.00. Following the transaction, the director owned 57,962 shares in the company, valued at $3,477,720. The trade was a 3.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.20% of the stock is currently owned by corporate insiders.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.